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Abstract
Background: Long non-coding RNAs (lncRNAs) are increasingly implicated as gene regulators and may ultimately
be more numerous than protein-coding genes in the human genome. Despite large numbers of reported lncRNAs,
reference annotations are likely incomplete due to their lower and tighter tissue-specific expression compared to
mRNAs. An unexplored factor potentially confounding lncRNA identification is inter-individual expression variability.
Here, we characterize lncRNA natural expression variability in human primary granulocytes.
Results: We annotate granulocyte lncRNAs and mRNAs in RNA-seq data from 10 healthy individuals, identifying
multiple lncRNAs absent from reference annotations, and use this to investigate three known features (higher
tissue-specificity, lower expression, and reduced splicing efficiency) of lncRNAs relative to mRNAs. Expression
variability was examined in seven individuals sampled three times at 1- or more than 1-month intervals. We show
that lncRNAs display significantly more inter-individual expression variability compared to mRNAs. We confirm this
finding in two independent human datasets by analyzing multiple tissues from the GTEx project and
lymphoblastoid cell lines from the GEUVADIS project. Using the latter dataset we also show that including more
human donors into the transcriptome annotation pipeline allows identification of an increasing number of lncRNAs,
but minimally affects mRNA gene number.
Conclusions: A comprehensive annotation of lncRNAs is known to require an approach that is sensitive to low and
tight tissue-specific expression. Here we show that increased inter-individual expression variability is an additional
general lncRNA feature to consider when creating a comprehensive annotation of human lncRNAs or proposing
their use as prognostic or disease markers.
Keywords: lncRNAs, expression variation, lncRNA identification, human genome annotation, granulocytes,
transcriptome, natural variation, lncRNA features
Background
Long non-protein coding RNAs (lncRNAs) have emerged
as a fundamental new layer of genomic information in di-
verse species [1]. They are considered to participate pri-
marily in mRNA gene regulation [2–5] and to play roles
in development and disease [6–8]. LncRNAs may be med-
ically relevant as prognostic factors, disease markers, and
drug targets [9–13]. To date, it is known that lncRNA
genes are abundant in the genomes of human ([14],
http://www.gencodegenes.org/stats.html), mouse ([15, 16],
http://www.gencodegenes.org/mouse_stats.html), other ver-
tebrates [17–20], plants [21], and simple model organisms
such as C. elegans [22] and yeast [23, 24]. Although large
numbers of lncRNAs have been identified, they have not
yet been completely annotated in any organism. Human
lncRNAs annotated by the GENCODE project comprise
the largest public dataset containing 15,877 lncRNA
genes (version 21: http://www.gencodegenes.org/stats/
archive.html#a21). Many human annotation projects use
cell lines [25], however, some also use primary tissues
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[14, 26]. An incomplete annotation may arise from two
known features of lncRNAs - low abundance and tight
tissue-specificity [14, 25]. Notably, lncRNA annotations dif-
fer not just between tissues, but also between closely related
cell types [27, 28]. Thus, a comprehensive map of all
lncRNA genes in the human genome would require
systematic and deep analysis of all human body cell
types. A recent attempt to define the human lncRNA
landscape used several thousand normal and malignant
samples and identified almost 47,000 new lncRNA
genes [29], supporting earlier predictions that lncRNAs
may outnumber protein-coding genes in human [30].
Relatively small numbers of mammalian lncRNAs have
been assigned a function. A new functional lncRNA data-
base lists only 181 human transcripts (http://www.lncrnad
b.org/, [31]). While it is possible that some lncRNA tran-
scription is a consequence of the local chromatin state
[32–34], the gap between annotation and proven function-
ality reflects the considerable challenges in the analysis of
non-coding compared to coding transcripts [35–39]. A
deeper knowledge of lncRNAs as a transcript class has
followed from genome-wide characterizations of their
biology and genomic features with mRNAs as a reference
point (reviewed in [30, 34, 40]). Both types of transcripts
are transcribed by RNAPII, possess histone modifications
typical of active or inactive genes and can be spliced,
capped, and polyadenylated (reviewed in [41]). However,
in addition to the basic lack of an open reading frame and
functional translation [42], some studies have identified
characteristics that differentiate lncRNAs from mRNAs.
In comparison to mRNAs, lncRNAs are generally found
to be more lowly-expressed, show higher tissue-specificity
and be enriched in the nucleus [14, 25]. Many lncRNAs
initiate from enhancer-like promoters that lack H3K4me3
histone modifications typical of standard mRNA pro-
moters [28, 43], or from repetitive transposable elements
normally absent from standard mRNA promoters [44]. In
terms of genome and biology features, lncRNAs are usu-
ally shorter with fewer exons and show inefficient co-
transcriptional splicing [45] and reduced stability [46].
They also show low sequence conservation and evolve fas-
ter than mRNAs [47–49].
One lncRNA feature not yet fully investigated in com-
parison to mRNAs that may influence identification and
functional characterization is their natural expression
variation. Protein-coding and lncRNA expression and
transcript structure have been shown to be dependent
on genetic variation in the human lymphoblastoid cell
line (LCL) collection [50–52]. Analysis of protein-coding
gene expression in whole human blood shows expres-
sion variation attributable to inter-individual (for ex-
ample, age, BMI) and lifestyle (fasting status, smoking)
differences, and technical issues such as sampling time,
collection and preparation [53, 54]. In this study we use
human primary granulocytes, a relatively pure cell type
routinely obtained in clinics from healthy individuals
and potentially useful diagnostically, to assess natural
variability of lncRNA expression. We first prepared an
RNA-seq dataset from 10 healthy individuals to define a
human granulocyte transcriptome, not previously avail-
able. From this we annotated 6,249 lncRNA transcripts
arising from 1,323 previously reported and 268 novel
lncRNA loci. We show that examining granulocytes
from multiple donors allows the identification of less
well expressed, less efficiently spliced, and more
granulocyte-specific lncRNAs. We then estimated
lncRNA expression reproducibility and variability in
granulocyte RNA-seq data from seven healthy individ-
uals sampled in three replicates with approximately 1-
month intervals. This inter- and intra-individual com-
parison demonstrated that although lncRNA expression
is reproducible between replicates from the same indi-
vidual, it is significantly more variable between individ-
uals compared to mRNAs. Analysis of multiple tissues
from the GTEx project [55] and lymphoblastoid cell
lines from the GEUVADIS project [50] supports this
conclusion and also shows that higher natural expression
variability compared to protein-coding genes is a general
feature of lncRNAs. Using the latter dataset we show
that natural expression variability markedly influences
lncRNA identification as the number of identified
lncRNAs increases with the number of donors analyzed
and does not reach saturation even with 120 donors. To-
gether, the data show that high expression variability of
lncRNAs is an important general feature, which not only
additionally distinguishes them from mRNAs, but also
will make it necessary to consider the number of indi-
viduals in strategies to comprehensively annotate and as-
sign putative functions to lncRNAs in the human
genome.
Results
Defining the human granulocyte lncRNA transcriptome
To annotate lncRNAs in human granulocytes we col-
lected samples from five male and five female healthy in-
dividuals of varying ages under standardized sampling
conditions and sequenced polyadenylated (PolyA+) RNA
(Fig. 1a, b, Additional file 1: Figure S1A and Supplemen-
tal Methods, Additional file 2A). Ribosome-depleted
RNA-seq, used for expression and splicing efficiency
analysis, was performed for seven donors (4 male do-
nors, 3 female donors) at three time points. To annotate
lncRNAs we aligned the PolyA+ RNA-seq data with
STAR [56] to obtain 757 million uniquely-mapped reads
of which 187.6 million were spliced (Additional file 2B,
C) and performed de novo transcriptome assembly using
Cufflinks and Cuffmerge [57]. The term ‘de novo’ is used
for transcripts/loci identified in this transcriptome
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assembly pipeline. Only multi-exonic transcripts longer
than 200 base pairs (bp) were retained and several filter-
ing steps applied to remove potential assembly artifacts
(Additional file 1: Figure S1). We next extracted multi-
exonic transcripts overlapping exons annotated as
protein-coding in GENCODE-v19 [58] and RefSeq [59]
and used them later to generate a de novo protein-
coding granulocyte mRNA annotation. We discarded
annotated GENCODE-v19 pseudogene transcripts. To
remove potential protein/peptide-coding transcripts, we
estimated transcript protein-coding capability using
RNAcode [60] and CPC [61]. We adjusted the criteria
for the output of the protein-coding potential estimation
pipeline (RNAcode score <18, CPC score <1.6) by ana-
lyzing well-known lncRNAs (Additional file 2D). We val-
idated these criteria by applying the pipeline to the
above public annotations; this identified the majority of
annotated lncRNAs as non-protein-coding, whereas the
majority of mRNAs were identified as protein-coding
(Additional file 1:Figure S1E). To avoid confusion in
later expression analysis we removed all lncRNAs over-
lapping a protein-coding gene in sense direction (for ex-
ample, intronic lncRNAs) from our analysis. The final de
novo lncRNA granulocyte annotation comprised 1,591
lncRNA loci (Additional file 3) expressing 6,249 lncRNA
transcripts (Additional file 4) with a mean of 3.9 tran-
script isoforms per locus, consistent with previous obser-
vations [14]. De novo lncRNA transcripts contained
13,058 unique exons from 5,612 non-overlapping exonic
regions. Protein-coding mRNAs were de novo annotated
in preference to using the public annotations to avoid
technical bias when comparing lncRNAs to mRNAs and
to assess the quality of our annotation (Additional file 1:
Figure S2). The de novo granulocyte mRNA annotation
comprised 10,092 mRNA loci (Additional file 5) express-
ing 132,864 transcripts (Additional file 6) with a mean of
13.2 transcripts per locus, consistent with previous ob-
servations [62]. We assigned de novo annotated lncRNAs
into three position-based classes relative to the nearest
protein-coding gene (Fig. 1c). The majority of lncRNA
loci (42 % comprising 659 loci) are intergenic, while
33 % (530 loci) are antisense and 25 % (402) are bidirec-
tional. Figure 1d shows an example of a de novo anno-
tated antisense lncRNA locus (green lines) absent from
public databases.
Identification of new lncRNA loci and isoforms
We compared our granulocyte de novo lncRNA annota-
tion to the most commonly used public annotations:
GENCODE-v19 (23,898 lncRNA transcripts) [58],
RefSeq (8,236 lncRNA transcripts) [59], and Cabili et al.
(21,630 lncRNA transcripts) [14] and found that 46 %
(736) of granulocyte de novo lncRNA loci were not
present in public annotations, while 54 % (855) had a
full or partial sense overlap with a publicly annotated
lncRNA. Exon comparison with the three public annota-
tions showed that we identified 5,694 new unique exons
from 2,986 non-overlapping exonic regions. This shows
that granulocytes have a specific lncRNA landscape that
needs to be defined prior to granulocyte transcriptome
analysis. To further assess the novelty of the annotated
granulocyte de novo lncRNA loci we examined the
MiTranscriptome lncRNA annotation based on 7,256
RNA-seq libraries from different human tissues, tumors,
and cell lines [29]. Together, this shows that while 83 %
of the lncRNA loci identified in this study can be found
in one of the four above lncRNA annotations, 268
(17 %) are not found (Fig. 1e). To test the reliability of
our granulocyte de novo lncRNA annotation we first de-
termined that over 80 % of transcripts were supported
by at least one exonic overlap with a spliced EST
(human ESTs, UCSC table browser) (Additional file 1:
Figure S3A). Second, the MiTranscriptome lncRNA an-
notation [29] provided an additional validation as 78 %
of our granulocyte de novo annotated lncRNAs were
supported by an exonic overlap with a spliced MiTran-
scriptome lncRNA (Additional file 1: Figure S3B) with a
median of 51 % exonic coverage of granulocyte de novo
lncRNAs by MiTranscriptome lncRNAs (Additional file 1:
Figure S3C). Public lncRNAs annotations had less overlap
(See figure on previous page.)
Fig. 1 Defining the lncRNA transcriptome of human primary granulocytes. a Sample processing overview. b LncRNA identification overview.
Granulocyte PolyA+ RNA-seq data from 10 donors was used for transcriptome assembly and filtered to create an annotation with 1,591 lncRNA
loci containing 6,249 lncRNA transcripts (Additional file 1: Figures S1-3). c Positional classification of lncRNA loci relative to the nearest protein-
coding gene. Twenty-five percent (402) are bidirectional (light gray), 33 % (530) are antisense (medium gray), and 42 % (659) are intergenic (dark
gray). Positional classes are illustrated underneath (blue: protein-coding gene, green: lncRNA). d Example of a novel granulocyte antisense lncRNA
locus. Top: 3' part of AJAP1 protein-coding gene (blue) and the novel antisense gra1110 lncRNA locus (green). Underneath: normalized to read
number RNA-seq signal from sample D2-2_pa_100ss (Additional file 2B); GENCODE-v19 protein-coding genes (blue lines) and de novo annotated
mRNAs (blue) and lncRNAs (green) showing lncRNA transcripts in locus gra1110 (Additional files 3, 4, and 6). e Overlap of granulocyte de novo
lncRNA annotations (green) with commonly used public lncRNA annotations (gray) (RefSeq: 8,236 lncRNA transcripts, GENCODE-v19: 23,898
lncRNA transcripts, Cabili [14]: 21,630 lncRNA transcripts) and the ‘MiTranscriptome’ annotation (brown) [29]. f Validation of granulocyte de novo
lncRNAs by cloning. Three de novo lncRNA loci (84, 152, 187) are shown (see also Additional file 1: Figures S4-S8). Top to bottom for each: scale
and chromosome, de novo lncRNA transcript annotation in each locus (green isoforms), cloning result (black lines) showing BLAT alignment of
the Sanger sequenced cloned cDNA
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with our annotation (Additional file 1: Figure S3B) and
showed poorer exonic coverage (Additional file 1: Figure
S3C) and thus provided support for fewer of our granulo-
cyte de novo lncRNA transcripts. In contrast, de novo
mRNAs were well covered by public mRNA annotations
and MiTranscriptome (Additional file 1: Figure S3B, D),
indicating that the poor lncRNA coverage may arise from
incomplete annotation of this transcript type in public an-
notations. Last, we used exon-spanning RT-PCR to test
granulocyte de novo annotated lncRNA splice junctions
(Additional file 2E). We confirmed 42 out of 46 tested
junctions from 22 granulocyte lncRNA loci. We also
cloned lncRNA transcripts from 18 granulocyte de novo
lncRNA loci not present in public annotations, to confirm
their full-length exon structure, continuity, and chromo-
some position (Additional file 1: Figures 1F, S4-S8 and
Additional file 2F). Cloned sequences were deposited in
GENBANK (Additional file 2G). In summary, we created
a reliable lncRNA transcriptome annotation in healthy hu-
man granulocytes that identifies 1,591 lncRNA loci of
which 17 % had not previously been described. Further-
more, we demonstrate that granulocyte de novo lncRNAs
in contrast to mRNAs are incompletely represented in
public annotations.
Non-mRNA-like features that may confound lncRNA
annotation
As a basis to investigate why our granulocyte de novo
annotation identified novel lncRNAs we classified them
(Fig. 2a) according to existing public annotations (PA) as
new lncRNA loci formed by ‘not in PA’ transcripts, or, as
‘known lncRNA loci’ formed by transcripts sharing all
exons (PA transcripts) or sharing at least one exon (iso-
form not in PA, see example in Fig. 2b representing a
novel isoform inside a publicly annotated lncRNA locus).
The distribution was uniform with 32 % (2,003) ‘PA
transcripts’, 37 % (2,235) ‘isoform not in PA’ and 31 %
(1,921) ‘not in PA transcripts’. We examined these three
lncRNA classes for four known lncRNA features (tissue-
specific expression, low expression level, PolyA+ enrich-
ment, and splicing efficiency), which could reduce their
identification in RNA-seq data compared to mRNAs.
To examine tissue-specificity we used publicly
available RNA-seq data from 34 human cell types
(ENCODE project (https://www.encodeproject.org),
Illumina Human Body Map Project (http://www.ebi.ac.uk/
gxa/experiments/E-MTAB-513) (Additional file 2H). These
data were aligned as in Fig. 1b and expression levels
calculated for de novo annotated granulocyte transcripts.
A transcript was considered granulocyte-specific if its
expression in granulocytes was at least three-fold higher
than in all other cell types. We found granulocyte-specific
expression of 32.5 % (1,927) de novo annotated lncRNA
transcripts and 4 % of de novo annotated mRNA
transcripts (Fig. 2c, Additional file 1: Figure S9A). This
trend was also observed for granulocyte-specific
expression over the whole locus, indicating it is not
an artifact of the greater number of mRNA isoforms
in the de novo annotation (Additional file 1: Figures
S9B and S10). The same analysis performed for
GENCODE-v19 transcripts that are annotated from
multiple sample types shows a decreased percentage
of lncRNAs (9.0 %) and mRNAs (1.5 %) identified as
granulocyte-specific, but a similarly large difference
(six-fold) between the two transcript types (Additional
file 1: Figure S9C). Analysis of tissue-specific expres-
sion performed separately for the three lncRNA tran-
script classes described above, shows that ‘in PA’
lncRNAs were more similar to GENCODE-v19 tran-
scripts being depleted for granulocyte-specific tran-
scripts compared to the bulk population (dashed green
line, Fig. 2c), while ‘not in PA’ and ‘isoform not in PA’
transcripts showed equal or increased granulocyte-
specificity.
Expression level is another feature strongly differenti-
ating lncRNAs and mRNAs. We calculated RPKMs of
granulocyte de novo lncRNA and mRNA transcripts in
the PolyA+ data used for the de novo annotation,
which showed that lncRNA transcripts are 10-fold less
abundant than mRNAs (0.65/6.14, respectively; Fig. 2d).
We noted that lncRNA/mRNA expression difference
was slightly reduced (seven-fold median difference)
when analyzing ribosomal-depleted datasets, indicating
lncRNA under-representation in PolyA+ RNA (Additional
file 1: Figure S11A). Comparing the three lncRNA tran-
script classes showed that ‘in PA’ transcripts display high-
est expression and ‘not in PA’ have lowest expression
among the three classes in both PolyA+ (see inset, Fig. 2d)
and ribosomal-depleted (Additional file 1: Figure S11F)
data.
The third feature that may influence lncRNA identifi-
cation is their reduced polyadenylation efficiency, as this
would lower abundance in the PolyA+ fraction usually
used for transcript identification. Given our above obser-
vation of poorer lncRNA representation in PolyA+ ver-
sus ribosome-depleted datasets, we compared transcript
abundance in these granulocyte datasets to estimate the
enrichment of lncRNAs and mRNAs in the PolyA+ frac-
tion (Fig. 2e). While mRNAs showed a median 2.6-fold
enrichment, lncRNAs showed a significantly lower me-
dian 1.6-fold enrichment (dashed green line, Fig. 2e).
We tested if this difference was influenced by low
lncRNA expression levels by splitting transcripts into ex-
pression bins (Additional file 1: Figure S12A). This
showed that independently of absolute expression levels,
lncRNAs show significantly lower PolyA+ enrichment
compared to mRNAs. Comparing the three lncRNA
transcript classes demonstrated that ‘not in PA’ and
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‘isoform not in PA’ transcripts showed significantly lower
PolyA+ enrichment than ‘in PA’ transcripts (Fig. 2e).
Inefficient splicing is a fourth feature likely to reduce
full-length lncRNA transcripts in the PolyA+ fraction.
We used granulocyte ribosomal-depleted RNA-seq to
calculate the splicing efficiency of every splice site in
lncRNA and mRNA transcripts and defined transcript
splicing efficiency as that of its most efficiently proc-
essed splice site (Additional file 1: Figure S13A, B). This
shows that splicing is significantly less efficient for
lncRNAs compared to mRNAs with a median splicing
efficiency of 88.13 % (dashed green line, Fig. 2f ) and
99.02 %, respectively. This splicing efficiency difference
is independent of expression level and also persists at
the locus level, that is, independently of the transcripts
number per locus (Additional file 1: Figures S12B and
S13C). The inefficient splicing of lncRNAs is supported
by the experimental validation of lncRNA spliced
products described above, which identified abundant
unspliced isoforms together with spliced isoforms (see
examples in Additional file 1: Figures S5B, S5C, S7A,
and S13B, E). Comparing the three lncRNA transcript
classes showed that ‘not in PA’ transcripts have lower
splicing efficiency than the bulk population analysis
(Fig. 2f ). The similar splicing efficiency in classes ‘iso-
form not in PA’ and ‘in PA’ arises from transcripts shar-
ing some splice sites. The reduced splicing of lncRNAs
‘not in PA’ was confirmed by analysis on the locus level
(Additional file 1: Figure S13D).
In addition to these four RNA biology features, we ex-
amined four genomic features. This showed that com-
pared to mRNAs, lncRNAs transcripts have significantly
fewer exons, their transcription starts are less CG-rich
but more repeat-rich, and their exons contain more re-
peats (Additional file 1: Figures S11B-E and S12C). With
the exception of the median exon number, these features
were more extreme in ‘not in PA’ and ‘isoform not in PA’
lncRNAs than in the class of ‘in PA’ lncRNAs. Together
this shows that new granulocyte lncRNAs identified in
this study have less mRNA-like features that further dis-
tinguish them from mRNAs compared to the bulk
lncRNA population. To support this claim we performed
the same analysis for MiTranscriptome mRNAs and
lncRNAs [29], which also shows that lncRNAs not in
public annotations have less mRNA-like features
(Additional file 1: Figures S14 and S15). Thus we show
that features such as tight tissue-specificity and low
expression, reduced enrichment in PolyA+ selected RNA
and reduced splicing efficiency, not only distinguish
lncRNAs from mRNAs, but by reducing their represen-
tation in the analyzed transcriptome make their identifi-
cation more challenging.
LncRNAs are reproducibly expressed within one donor
but vary between donors
We next investigated reproducibility of lncRNA expres-
sion in healthy individuals to assess if this could also influ-
ence the lncRNA discovery. To estimate expression
reproducibility within or between donors, we examined
expression in granulocytes from seven donors sampled at
three time points spaced by at least 1 month (Fig. 3a,
Additional file 2A). These 21 samples were subject to
ribosome-depleted RNA-seq (Additional file 2B) aligned
with STAR and expression levels were determined of all
(See figure on previous page.)
Fig. 2 LncRNAs not in public annotations show less mRNA-like features. a Distribution of 6,249 granulocyte de novo annotated lncRNA transcripts
according to coverage by three commonly used public annotations (PA): RefSeq, GENCODE-v19, Cabili [14, 58, 59]. Known lncRNA loci contain
two transcript types: ‘PA transcripts’ that show full exonic overlap with an annotated lncRNA transcript (32 %, 2,003 transcripts, dark gray), or ‘isoform
not in PA’ transcripts, that can share exons but contain one or more additional exons not present in public annotation (37 %, 2,331 transcripts
medium gray). New lncRNA loci: contain 1,921 ‘not in PA’ transcripts (31 % of lncRNA transcripts identified in granulocytes, light gray). b An example
of a publicly-annotated lncRNA locus (GENCODE-v19 AC007950.1) that contains additional upstream exons not in PA, from sample D2-2_pa_100ss
(Additional file 2B). The annotation identifies locus gra912 (thick green bar). The annotated lncRNA isoforms of locus gra912 with alternative transcription
start sites (TSS) are shown underneath as gray lines (the shorter PA transcript is shown in black for comparison). c Granulocyte-specificity analysis. Bar
plot shows the percentage of granulocyte-specific (purple) and not-specific (light gray) transcripts de novo annotated in granulocytes. Each bar shows
the percentage of granulocyte-specific transcripts for each transcript class while the dashed green line shows the percentage for all lncRNAs together.
d Average expression level (RPKM) in granulocyte PolyA+ RNA-seq samples used for annotation. The median values are: all mRNA transcripts (blue): 6.14,
all lncRNA transcripts (green dashed line): 0.65, lncRNA transcripts ‘in PA’ (dark gray): 1.00, lncRNA transcripts ‘isoform not in PA’ (medium gray): 0.68,
lncRNA transcripts ‘not in PA’ (light gray): 0.47. e PolyA+ enrichment of de novo granulocyte annotated transcripts calculated as a ratio between
abundance of a transcript in PolyA+ RNA and abundance in total ribosome-depleted RNA. Transcript abundance (RPKM) is averaged among all PolyA+
RNA-seq samples or all total RNA-Ribosomal depleted RNA-seq samples. Transcripts not detected in total RNA-seq data (average RPKM <0.2) were not
analyzed. The median values are: all mRNA transcripts (blue): 2.62, all lncRNA transcripts (dashed green line): 1.56, lncRNA transcripts ‘in PA’ (dark gray):
1.80, lncRNA transcripts ‘isoform not in PA’ (medium gray): 1.54, lncRNA transcripts ‘not in PA’ (light gray): 1.29. f Splicing efficiency of de novo
granulocyte annotated transcripts. Only transcripts with average RPKM >0.2 in 21 ribosomal-depleted RNA-seq samples were analyzed and the
efficiency of the most efficiently-spliced site in each transcript is plotted. The median values are: all mRNA transcripts: 99.02 %, all lncRNA
transcripts: 88.13 %, lncRNA transcripts ‘in PA’: 87.18 %, lncRNA transcripts ‘isoform not in PA’: 90.90 %, lncRNA transcripts ‘not in PA’: 77.97 %.
Remarks to boxplots d, e, and f: the box plot displays the full population but P values are calculated using Mann–Whitney U test on equalized
population sizes. *0.001 < P < 10-5, **10-5 < P < 10-10, ***P < 10-16. Green asterisks indicate the significance of the difference between mRNAs and
all lncRNAs (only the median level is plotted as a dashed green line). Outliers are not displayed
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de novo annotated lncRNAs and mRNAs. We first tested
if annotated transcripts were reproducibly expressed
within one donor, that is, the three time points for each
donor should show consistent lncRNA expression (RPKM
>0.2) or absence (RPKM ≤0.2) of expression (Fig. 3b top).
This analysis was performed separately for transcripts with
different expression levels. Expression levels for each
donor were calculated by averaging RPKMs from the three
time points and a transcript was placed into a bin accord-
ing to its maximal expression level among the seven do-
nors. We counted the number of reproducibly-expressed
transcripts and found that lncRNAs are less reproducible
in bins 1 and 2, but above RPKM >2 almost all de novo
annotated lncRNAs and mRNAs (99–100 %) were repro-
ducibly detected within one donor. In contrast, comparing
expression between the seven donors showed consistent
lower expression reproducibility of lncRNAs compared to
mRNAs (Fig. 3b, bottom). In the three highest expression
bins, mRNAs showed 100 % reproducibility while lncRNA
transcripts only reached 95 %. In summary, this qualitative
analysis shows that, above an expression threshold (RPKM
>2), lncRNAs are as reproducibly expressed as mRNAs
within replicates from one donor. However, lncRNAs
show less reproducible expression than mRNAs between
different donors.
LncRNAs show high expression variability between
donors
We quantitated the extent of expression variability be-
tween the seven donors by calculating the standard devi-
ation of granulocyte de novo lncRNA and mRNA
expression (Fig. 4a, b). As RPKM is a parametric value
and ranges from 0.2 (the used expression cutoff) to several
thousand, we normalized standard deviation of expression
for each gene between donors by the mean of expression
among the seven donors (thus calculating the value also
known as the coefficient of variation). We performed this
analysis calculating variability of expression for each tran-
script separately (Fig. 4a), and expression of the whole
locus disregarding identified exon structures (Fig. 4b,
Additional file 1: Figure S10). Both analyses showed that
lncRNAs display significantly higher variability than
mRNAs (P <10–16). LncRNA and mRNA expression
variability between donors (inter-individual) was signifi-
cantly higher than between the replicates from one donor
(intra-individual). In addition, both inter- and intra-
individual expression variability of lncRNAs exceeded that
of mRNAs (Additional file 1: Figure S16). The high
inter-individual variability of lncRNA expression
allowed unsupervised clustering of the three time point
samples according to each of the seven donors (Fig. 4c),
that validates their use as replicates.
LncRNA expression is generally lower than that of
mRNAs (Fig. 2d, Additional file 1: Figure S11A), which
could bias the expression variability analysis, as lower
expression will correlate with higher normalized stand-
ard deviation values. We controlled for this by distribut-
ing transcripts and loci into expression bins (Additional
file 1: Figure S17). This showed that while variability
anti-correlates with expression level for both lncRNAs
and mRNAs, lncRNAs analyzed at the transcript or loci
level show consistently more expression variability than
Fig. 3 Reproducibility of de novo lncRNA and mRNA expression. a Study overview. Top: the granulocyte de novo transcriptome annotation was
generated from 10 healthy donors. Bottom: seven donors were sampled at three time points spaced by ≥1 month (Additional file 2A) and RNA
was sequenced to assess intra-individual (using three time points from one donor) and inter-individual (using samples from seven different donors)
expression reproducibility. b Granulocyte intra-individual (top) and inter-individual (bottom) expression reproducibility for de novo annotated lncRNAs
(green) and mRNAs (blue). Transcripts detectable (RPKM >0.2) at each of three time points or not detected (RPKM <0.2) at any time point in all
seven donors show intra-individual reproducibility. Transcripts detectable in each of seven donors (average RPKM of three replicates >0.2) show
inter-individual reproducibility. Five expression bins were used: (1) 0.5 < RPKM ≤1; (2) 1 < RPKM ≤2; (3) 2 < RPKM ≤4; (4) 4 < RPKM ≤8; and (5)
RPKM >8 (n = transcript number per bin). Chromosomes X, Y were discarded
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mRNAs, independent of absolute expression level. We
additionally plotted expression variability against mean
expression between all donors for lncRNA and mRNA
transcripts and loci (Additional file 1: Figure S18A, B).
This showed that the trend lines of the anti-correlation
between variability and expression level are clearly dis-
tinct for lncRNAs and mRNAs at both transcript and
loci level, with lncRNAs displaying higher variability.
Thus, high natural expression variability is not an
artifact of the general low expression of lncRNAs. To
identify the number of lncRNA and mRNA transcripts
and loci significantly variable between donors we applied
an ANOVA test (aov function in R [63]) to expression
values in all the 21 (that is, seven donors sampled three
times) ribosomal depleted RNA-seq samples. We find
that 23.9 % (1,069) of lncRNA transcripts but only 4.2 %
of mRNA transcripts are differentially expressed be-
tween the seven donors (transcripts RPKM >0.2, Fig. 4d).
This trend persisted when applying an ANOVA test to
expression over whole loci (Fig. 4d, 15.5 % and 4.4 % for
lncRNA and mRNA loci, respectively). Importantly, this
difference between lncRNAs and mRNAs was persistent
when analyzing different expression bins (Additional file 1:
Figure S19A). Figure 4e shows an example of a signifi-
cantly variable lncRNA expressed from chromosome 15.
Among the four displayed tracks donors 3 and 4 show
higher expression, consistent among three replicates,
while donors 1 and 2 show low expression consistent
among replicates. Since 25 % of de novo annotated
lncRNAs are bidirectional and likely share a promoter
with an mRNA (Fig. 1c), we examined if this class resem-
ble mRNAs in having less expression variability. Figure 4f
shows that bidirectional lncRNA transcripts more closely
resembled mRNAs and were significantly less variable
than antisense or intergenic lncRNAs and this trend was
also observed in all expression bins and over the whole
locus (Additional file 1: Figure S20A-C).
Publicly annotated lncRNAs show less expression
variability
To further confirm high lncRNA expression variability
and to investigate its impact on lncRNA identification,
we analyzed expression variability of publicly annotated
(Additional file 1: Figure S21A, B) and of MiTranscrip-
tome (Additional file 1: Figure S22A, B) lncRNAs and
mRNAs in our granulocyte RNA-seq data. All annota-
tions confirmed high lncRNA expression variability
compared to mRNAs. However, the extent of the
lncRNA/mRNA difference was reduced when analyzing
public annotations compared to the MiTranscriptome
annotation and our de novo granulocyte annotation,
which both identified numerous novel lncRNAs. We
then estimated expression variability separately for the
three lncRNA classes described in Fig. 2a, and found
that transcript types ‘not in PA’ and ‘isoform not in PA’
showed significantly higher variability between the seven
donors, compared to ‘in PA’ transcripts (Fig. 4g) and this
trend was observed in all expression bins (Additional file 1:
Figure S23A) and also when analyzing expression over
whole locus for ‘new’ and ‘known’ lncRNA loci (Additional
file 1: Figure S23B, C). To test this further, we analyzed ex-
pression variability of MiTranscriptome lncRNAs classified
according to their presence in public annotations (as de-
scribed in Additional file 1: Figure S14D). This showed that
(See figure on previous page.)
Fig. 4 LncRNAs are more variably expressed than mRNAs. a, b Genome wide inter-individual variability (normalized standard deviation between
expression of each transcript/locus in granulocytes from seven donors) of de novo granulocyte lncRNA (green) and mRNA (blue) transcripts (a)
and loci (b). Donor expression level is averaged from three replicates (***P <10–16). Median values: lncRNA transcripts: 0.29, mRNA transcripts: 0.15,
lncRNA loci: 0.26, mRNA loci: 0.15. c LncRNA inter-individual expression variability allows correct clustering (normalized level among seven donors)
of three time points per donor. Maximum transcript expression among all 21 samples is set to 1 (red), minimum is 0 (white). Clustering was performed
using pheatmap function in R (clustering_distance_rows = ‘euclidean’, clustering_distance_cols = ‘correlation’). Only transcripts detected (RPKM >0.2) in
at least one of the total RNA-seq samples were analyzed. Chromosomes X, Y were discarded. d Significance of granulocyte de novo lncRNA and mRNA
expression variability in seven donors assessed by ANOVA test (the three time points are used as replicates). Bars show the percentage of significantly
variable lncRNA (green) and mRNA (blue) transcripts (left) and loci (right). Criteria for calling a transcript/locus ‘significantly variable’: ANOVA test P value
<0.01, FDR (Benjamini-Hochberg correction) <0.05, fold change between highest and lowest expression in seven donors >3. Only transcripts/loci with
RPKM >0.2 in at least one donor are included. Chromosomes X and Y were discarded from the analysis. Total number analyzed: lncRNA transcripts
4,464, mRNA transcripts 119,412, lncRNA loci 658, mRNA loci 5,797. e Example of a significantly variable transcript from lncRNA locus gra896. Top: an
alternative gra896 TSS overlaps the publicly-annotated lncRNA RP11-1008C21.1 locus. Underneath: normalized total RNA-seq signal for three replicates
of four donors scaling from -0.001 (reverse strand, light gray) to 0.004 (forward strand, black). Calculated expression level of the annotated lncRNA
transcript marked with * is shown for each RNA-seq track. Significance result for this transcript among seven donors: ANOVA test P = 10–7, FDR
(Benjamini-Hochberg) = 10–6, expression fold change = 5.2). f Bidirectional lncRNA transcripts show reduced expression variability. Boxplots show
inter-individual variability of lncRNA transcripts split according to their position relative to protein-coding genes as in Fig. 1c. Median normalized
standard deviation values: bidirectional: 0.22, antisense: 0.29, intergenic: 0.30. Dashed blue line indicates median expression variability of all de novo
mRNA transcripts. g Inter-individual expression variability is lower for known ‘in PA’ lncRNA transcripts compared to those newly annotated in granulocytes
(‘not in PA’ and ‘isoform not in PA’). Median normalized standard deviation values: ‘not in PA’: 0.33, ‘isoform not in PA’: 0.30, ‘in PA’: 0.24. Dashed blue line
indicates median expression variability of all de novo mRNA transcripts. Remarks to boxplots a, b, c, g: Transcripts/loci not expressed (RPKM <0.2) in any
of seven donors (total RNA-seq data) and data from chromosomes X, Y were discarded and outliers are not displayed. The box plot displays the full
population but P value is calculated using Mann–Whitney U test on equalized sample size. n.s. not significant, ***P <10–16
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‘not in PA’ and ‘isoform not in PA’ MiTranscriptome
lncRNAs displayed higher expression variability (Additional
file 1: Figure S22C), consistent with results for the de novo
granulocyte lncRNA annotation. Together this supports
our arguments above, that lncRNAs not in public annota-
tions have less mRNA-like features.
A list of robustly or variably expressed lncRNAs in human
primary granulocytes
Following the discovery of high intra- and inter-individual
expression variability of lncRNAs we sought to generate a
list of robustly expressed and variably expressed granulo-
cyte lncRNAs as a resource. To generate the robustly
expressed list we filtered 6,249 lncRNA transcripts in our
annotation (that is, the set of transcripts that ‘can be’
expressed in granulocytes) to identify those detected
(RPKM >0.2) in all replicate samples from seven donors.
This gave a robustly expressed annotation of 2,490 tran-
scripts from 393 lncRNA loci (Additional file 7A). We ap-
plied stricter criteria and required a higher level of
expression (RPKM >1) in every sample to produce another
annotation of ‘well-expressed robust’ lncRNAs in gran-
ulocytes with 817 transcripts from 115 lncRNA loci
(Additional file 7B). A list of significantly variably expressed
(defined as in Fig. 4d) lncRNAs with 1,069 transcripts
from 214 lncRNA loci is provided in Additional file 8.
LncRNAs expression variability in lymphoblastoid cell
lines (LCL)
To test our finding of high lncRNA expression vari-
ability in an independent cell type and with larger
donor numbers, we analyzed GEUVADIS project data
(http://www.geuvadis.org/web/geuvadis/rnaseq-project
[50]) consisting of PolyA+ non-stranded RNA-seq of
lymphoblastoid cell lines (LCL) sampled once from 462
healthy individuals of various ages from five population
groups (Fig. 5a) (ENA http://www.ebi.ac.uk/ena/data/
view/ERR188021-ERR188482). Since LCL are a different
cell type to granulocytes, we created a de novo LCL anno-
tation via our pipeline (Additional file 1: Figure S24A).
From the list of 462 samples, we used RNA-seq data from
20 unrelated donors (2 female donors and 2 male
donors from each population with a total of 522
(26.1 million reads/donor) million uniquely mapped
reads and 177.8 million spliced reads) grouped into
five pools (Additional file 2I). The resulting LCL
lncRNA transcriptome consisted of 2,611 lncRNA loci
(Additional file 9) formed by 8,560 lncRNA transcripts
(Additional file 10) with a mean of 3.3 transcripts per
locus (Fig. 5b). The lncRNA transcripts contained 17,009
unique exons from 9,379 non-overlapping regions. We
also annotated 12,241 de novo mRNA loci formed by
124,799 transcripts, with a mean of 10.1 transcript per
locus. The overlap of LCL and granulocyte de novo
lncRNA transcriptomes comprised only 536 loci (21 %)
whereas the de novo mRNA transcriptomes overlapped by
9,357 loci (76 %), which is consistent with lncRNA high
tissue-specificity (Fig. 5c). The increase in lncRNA loci
number from 1,591 in granulocytes, to 2,611 in LCL may
reflect increased transcriptional activity of LCL compared
to primary granulocytes or the two-fold increase in donor
number used for annotation (see data below). Comparison
of the LCL de novo lncRNA annotation to public annota-
tions and MiTranscriptome showed that 2,316 (89 %) of
LCL lncRNA loci are covered by the four lncRNA annota-
tions while 295 (11 %) are not found (Fig. 5c). The LCL an-
notation quality was verified in a similar manner as for the
granulocyte annotation (Additional file 1: Figure S24B-G).
LncRNA classification by coverage from public annotations
shows that 1,536 are known loci containing 3,363 (39 %)
‘in PA’ while 3,111 (36 %) are ‘isoform not in PA’ tran-
scripts, and 1,075 are new loci formed by 2,086 (25 %) ‘not
in PA’ transcripts (Additional file 1: Figure S25). Exon
comparison showed that de novo lncRNA annotation
in LCL contained 6,113 unique exons not present in
public annotations from 4,150 non-overlapping exonic
regions. Similar to granulocytes, LCL lncRNA transcripts
not in public annotations show less mRNA-like features
(Additional file 1: Figure S26).
We used the LCL de novo annotation to calculate the
RPKM of every transcript and locus in all 462 donors.
An ANOVA test could not be applied due to the absence
of donor replicates, but inter-individual variability was
calculated from the normalized standard deviation of ex-
pression between all donors. Comparing lncRNAs to
mRNAs showed that lncRNAs are significantly more
variable both when calculating expression of transcripts or
over whole loci (Fig. 5d, e). We controlled for expression
level by distributing transcripts or loci to expression bins as
described above and found that except for bin1 transcripts,
lncRNAs were significantly more variable in expression
than mRNAs (Additional file 1: Figure S27). To complete
the comparison with the granulocyte data, we found LCL
bidirectional lncRNAs to be significantly less variable than
intergenic lncRNAs in all expression bins (Additional file 1:
Figure S28). In addition, LCL de novo lncRNAs not covered
by public annotations (‘not in PA’ transcripts) show signifi-
cantly more expression variation than publicly annotated
transcripts (Fig. 5f, Additional file 1: Figure S29). This
analysis of an independent cell type with an independent
sample collection and processing method from a larger
number of donors supports our finding of high inter-
individual lncRNA expression variability.
LncRNA expression variability is increased in multiple
human tissues
The above analysis shows high lncRNA expression vari-
ability relative to mRNAs in a primary human cell type
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(granulocytes) as well as in cell lines immortalized from
lymphocytes. To test if this is a general phenomenon in
human tissues, we obtained access to the GTEx project
RNA-seq data [55, 64]. We downloaded RNA-seq data
for nine human tissues: LCL, adipose, artery, cerebellum,
heart, lung, muscle, nerve, and thyroid from 20 indi-
viduals per tissue (Additional file 2J). We used the
MiTranscriptome transcript annotation derived from
multiple tissue types [29], to calculate lncRNA and mRNA
expression in GTEx samples and then estimated expres-
sion variability as described above using 20 donors per tis-
sue (Fig. 6). This shows that lncRNAs are significantly
more variable than mRNAs in all the analyzed tissues. We
performed a binned expression control as described above
Fig. 5 GEUVADIS RNA-seq data confirm increased lncRNA expression variability. a Sample processing overview: 462 lymphoblastoid cell lines
(LCL) established from healthy donors by EBV transformation were processed by the GEUVADIS RNA-seq Project [50]. b LncRNA identification
overview. We picked 20 unrelated donors (total of 522 million uniquely mapped reads) from 462 donors and processed the raw RNA-seq data
through the same pipeline used to annotate lncRNAs in granulocytes (Additional file 1: Figure S24). The resulting LCL lncRNA transcriptome
contained 2,611 lncRNA loci formed by 8,560 lncRNA transcripts. c Top: overlap between LCL and granulocyte de novo transcriptome annotations
created in the study. A total of 536 of 2,611 LCL lncRNA loci overlap granulocyte loci. A total of 9,357 of 12,241 LCL de novo mRNA loci overlap
granulocyte loci. Bottom: overlap of de novo lncRNA annotation in LCL with commonly used public annotations (PA): RefSeq, GENCODE-v19, and
Cabili [14, 58, 59], and the MiTranscriptome annotation [29] identifies 295 new lncRNA loci. Of these, only 18 loci overlap the de novo lncRNA
granulocyte annotation. d, e LncRNAs show higher expression variability than mRNAs in LCL. The boxplots show inter-individual variability of LCL
lncRNA (green) and mRNA (blue) transcripts (d) and loci (e). Inter-individual variability is estimated by calculating standard deviation between
expression of each transcript/locus in 462 donors normalized to the mean expression. Both transcripts and loci variability is significantly (***P <10–16)
different between lncRNAs and mRNA. Median values: lncRNA transcripts: 0.56, mRNA transcripts: 0.24, lncRNA loci: 0.51, mRNA loci: 0.25. f Inter-individual
expression variability is higher for newly annotated lncRNA transcripts in LCL. Boxplot shows inter-individual expression variability of LCL lncRNA transcripts
split according to coverage by public annotations (PA), which is higher for ‘not in PA’ and ‘isoform not in PA’ lncRNA transcripts compared to ‘in PA’.
Median normalized standard deviation values: not in PA: 0.66, isoform not in PA: 0.58, in PA: 0.46. Blue dashed line indicates median expression variability
of all de novo mRNA transcripts in (d). Remarks to boxplots d, e, f: transcripts or loci not expressed (RPKM <0.2) in any of the 462 donors were discarded.
The box plot displays the full population but P value is calculated using Mann–Whitney U test on equalized sample size (**P <10–10, ***P <10–16). Data from
chromosomes X, Y were discarded and outliers are not displayed
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and found that, apart from bin 1 that showed inconsistent
results in two tissues, all nine tissues showed a significant
increase of lncRNA expression variability independent of
expression level (Additional file 1: Figure S30). Together
with the above data on granulocytes and LCLs, this dem-
onstration of increased lncRNA expression variability rela-
tive to mRNAs in multiple human tissues indicates that it
is a general phenomenon inherent to all human tissues
and a new lncRNA feature.
Increased expression variability affects lncRNA
identification
We demonstrated above the high lncRNA inter-individual
expression variability in diverse human tissues (Figs. 4a, b,
5d, e and 6) as well as the increased expression variability
of novel compared to known lncRNAs (Figs. 4g and 5f,
Additional file 1: Figure S22C). We asked if this expres-
sion variability feature could influence lncRNA identifica-
tion. Figure 7a shows an example of a highly variably
expressed de novo annotated LCL lncRNA not covered by
public annotations (but identified with different exon
models in [29]) that is well expressed (RPKM >1) in one
out of 462 donors in the GEUVADIS project dataset,
expressed at a low level (RPKM >0.2) in 93 donors and
not detected (RPKM <0.2) in the remaining 368 donors. It
is likely that such a lncRNA has a low chance of discovery
when analyzing few individuals. We hypothesized that
adding more individuals to the identification pipeline
may increase the chance of identifying highly variably
expressed lncRNAs. At the same time, given the relatively
low inter-individual expression variability of mRNAs, we
would expect to identify a relatively constant number of
mRNA loci.
We tested this by de novo annotating lncRNAs and
mRNAs from a variable number of individuals. We
picked 120 GEUVADIS LCL donors (Fig. 7b, Additional
file 11A), unified the data by sampling 25 million
paired-end reads from each donor and created 30 pools,
each with four donors (two male and two female do-
nors) with a total of 100 (25 × 4) million reads. From
the 30 pools we created 30 LCL de novo transcriptome
assemblies using Cufflinks. We randomly picked 1, 2, 3,
4, 5, 6, 8, 10, 15, 20, 25 (using three replicates of ran-
dom picking), and 30 assemblies, which corresponded
to 4, 8, 12, 16, 20, 24, 32, 40, 60, 80, 100, and 120 do-
nors, respectively, and applied Cuffmerge and the de
novo transcriptome annotation pipeline to each group
of assemblies (Additional file 1: Figure S31A, B and
Additional file 11B). Only one pool (100 million reads)
was fed at a time into the assembly pipeline, thus
the sensitivity of Cufflinks was unchanged. In
addition, assemblies but not reads were merged at
this stage. Different number of assemblies fed into
our annotation pipeline produced multiple lncRNA/mRNA
annotations with different numbers of loci and tran-
scripts. We plotted the number of mRNA and
lncRNA loci (averaged from the three replicates de-
scribed above) versus the number of donors used
(Fig. 7c, Additional file 11C). This showed that while
lncRNA loci number (green lines) grew three-fold with
increasing donor number, from 1,382 loci obtained
from four donors to 4,166 obtained from 120 donors,
Fig. 6 GTEx RNA-seq data show increased lncRNA expression variability in multiple human tissues. Inter-individual variability of multi-exonic
MiTranscriptome lncRNA (green) and mRNA (blue) transcripts analyzed in GTEx RNA-seq dataset [64]. Twenty donors per tissue are analyzed (Additional
file 2J). Standard deviation is normalized to the mean expression among all 20 analyzed donors for each tissue. Only transcripts expressed in the given
tissue in at least one donor (RPKM >0.2) are displayed. Number of transcripts in each box from left to right: LCL (lncRNAs: 28,571; mRNAs: 102,449),
adipose (lncRNAs: 38,060; mRNAs: 113,688), artery (lncRNAs: 29,965; mRNAs: 108,082), cerebellum (lncRNAs: 44,912; mRNAs: 115,039), heart (lncRNAs:
32,827; mRNAs: 111,564), lung (lncRNAs: 39,909; mRNAs: 117,901), muscle (lncRNAs: 31,507; mRNAs: 106,099), nerve (lncRNAs: 39,167; mRNAs: 115,038),
and thyroid (lncRNAs: 40,099; mRNAs: 116,206). Median expression values from left to right: LCL: 0.55, 0.27, adipose: 0.66, 0.32, artery: 0.59,
0.30, cerebellum: 0.60, 0.33, heart: 0.66, 0.36, lung: 0.63, 0.31, muscle: 0.85, 0.41, nerve: 0.54, 0.26, and thyroid: 0.56, 0.27. The box plots
display the full population but P values are calculated using Mann–Whitney U test on equalized sample size (***P <10–16). Data from
chromosomes X, Y were discarded and outliers are not displayed
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the number of mRNA loci (blue lines) shows a much
lower level of increase from 12,085 (four donors) to
12,857 loci (120 donors). This supports the hypothesis
that adding more individuals to the identification
pipeline increases the number of lncRNA loci but not
the number of mRNA loci.
Fig. 7 Increasing donor number identifies more lncRNA loci. a Example of a highly variable LCL lncRNA locus lcl1580 not in public annotations.
GENCODE-v19 annotates lncRNA RP11-555G19.1 and protein coding gene AP003062.1 transcribed in antisense direction to lcl1580 (top). Normalized
non-strand-specific PolyA+ RNA-seq signal for three donors is displayed (scaling from 0 to 0.6). RPKM of the *transcript isoform is shown for each
sample. b Analysis overview. GEUVADIS project LCL RNA-seq data from 120 donors was used to create 30 data pools (each with 100 million reads from
two female (red) and two male (blue) donors) and to assemble 30 transcriptomes (Methods). An increasing number of assemblies (corresponding to
from 4 to up to 120 donors) was merged to serve as input into the de novo lncRNA and mRNA identification pipeline (Additional file 1: Figure S1A).
This created a series of LCL de novo lncRNA and mRNA annotations from an increasing number of donors. c LCL de novo lncRNA (green) and mRNA
(blue) loci number annotated using increased donor number. Left: Y-axis for lncRNA loci (green). Right: Y-axis for mRNA loci (blue). The range of values
is set to 3,500 on both Y-axes. Maximum number of lncRNA / mRNA loci annotated (at 120 donors): 4,166 / 12,857. Error bars: standard deviation of loci
number between three replicates of random picking for each number of assemblies used (Additional file 11C)
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In contrast to the loci analysis, the number of tran-
script isoforms increased with similar kinetics for both
lncRNAs and mRNAs (approximately seven-fold in-
crease from four to 120 donors; Additional file 1: Figure
S31C). The difference between lncRNAs and mRNAs is
that an increasing donor number allows identification of
an increasing number of transcript isoforms inside a
stable number of mRNA loci, while lncRNAs retain a
low median number of transcripts per locus and increase
the number of loci annotated in the genome (Additional
file 1: Figure S31D). Note that we did not expect to find
non-annotated mRNAs loci since the mRNA de novo
identification pipeline was limited to annotated mRNA
genes. If the analysis did identify non-annotated mRNA
loci they would be recognized among lncRNA candi-
dates that were filtered by the pipeline step that esti-
mated transcript protein-coding capability. However, this
step only removed a low-level increase from 83 (four do-
nors) to 198 (120 donors) loci (Additional file 1: Figure
S31E). The slight increase in mRNA loci number with
increasing donor number (Fig. 7c) likely arises from high
inter-individual expression variability of a small number
of mRNAs in LCLs. The larger increase in lncRNA loci
number also arises from identifying more highly variable
annotated lncRNAs when analyzing more donors, but
also potentially by identifying novel lncRNA loci.
Assembling transcriptomes from pools of 100 million
paired-end read does not increase Cufflinks sensitivity
(Additional file 1: Figure S31A), but including more do-
nors into the identification pipeline naturally increased
the number of transcriptome assemblies merged and
therefore the total amount of the RNA-seq data analyzed
(from 1 to 30 × 108 sequencing reads). To control that
this strategy did not only lead to the identification of
marginally-expressed lncRNAs we plotted the RPKM of
lncRNAs added to annotation with the addition of more
donors (Additional file 1: Figure S32). This shows that
median level of expression (in at least one donor used
for identification) of newly-identified lncRNAs is RPKM
of approximately 1, which means that 50 % of the
newly-identified lncRNA transcripts are well-expressed
(RPKM >1). This median level also does not decrease for
transcripts that are only found with large donor num-
bers. In addition, we analyzed the dynamics of lncRNA
identification with increasing the donor number in dif-
ferent expression bins (Additional file 1: Figure S33).
This shows that lncRNAs from high-expression bins
contribute substantially to the overall increase in
lncRNA loci and transcript number. For example, four
donor annotations identified 314 lncRNA transcripts ini-
tiating from 152 different loci in bin4 (that is, at least
one donor used for identification expresses the transcript
with 4 < RPKM< 8), while annotating from 120 donors
identified 3,518 bin4-lncRNA transcripts initiating from
610 loci. Thus, while marginally-expressed lncRNAs are
identified by adding more donors to the analysis, they only
constitute a fraction of the newly-identified transcripts.
Both controls show that identification of an increasing
number of lncRNAs cannot be solely attributed to sto-
chastic sampling sensitivity and identification of lowly-
expressed transcripts, but likely arises from genuine
expression variability between individuals.
We next asked if the lncRNA loci identified with in-
creased donor numbers were new or known loci (as de-
fined in Fig. 2a) and what were the dynamics of their
identification. To do this we plotted the normalized
number (the number of loci at 120 donors set to 100 %)
of known (dark gray) and new (light gray) lncRNA loci
versus donor number (Figure S34 in Additional file 1:
Figure S34 and Additional file 11C). For comparison the
same plot shows the dynamics of mRNA (dashed blue
line) and all lncRNA (dashed green line) identification
from the data in Fig. 7b. This shows that although the
number of known lncRNA loci increases with donor
number from 948.5 (four donors,) to 2,103 (120 donors),
the number of novel lncRNA loci shows a more striking
increase from 433.7 to 2063 loci (2.2-fold and 4.8-fold,
respectively; Additional file 1: Figure S34) (note that
non-integer loci numbers arise from averaging three rep-
licates). While mRNA loci identification plateaued with
four donors, the known lncRNA loci identification curve
starts to plateau with >80 donors, but the new lncRNA
identification curve does not plateau up to 120 donors.
Finally, we used the most comprehensive de novo an-
notation from 120 donors as a reference transcriptome
to build a ‘donor saturation curve’ to test how well this
annotation can be recreated using fewer individuals. We
counted the number of reference 120 donor lncRNA
and mRNA loci identified (defined by >50 % coverage,
Additional file 1: Figure S35A, top, Additional file 11D)
using a reduced number of donors. The resulting curve
saturates for mRNAs, but does not saturate for lncRNAs
even with 120 individuals. Only 27 % of lncRNA loci
identified with 120 donors were identified using four do-
nors, this increased to 50 % at 20 donors and thereafter
continuing to rise. The difference between known and
new lncRNA loci was consistent with observations in
Additional file 1: Figure S34. We also assessed how well
the exon structure of mRNAs and lncRNAs from the
reference 120 donor annotation was recreated by anno-
tations obtained using fewer donors (Additional file 1:
Figure S35B). Median exonic coverage of mRNAs was
above 90 % just using four donors, whereas lncRNAs re-
quire 80 donors to reach similar levels of exonic cover-
age. In summary, these analyses show that increasing the
donor number will identify more lncRNA loci, however,
the donor number required is vastly in excess of that re-
quired for mRNAs.
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Discussion
An appreciation of the need to define the lncRNA land-
scape of the whole human genome is increasing with the
number of known lncRNAs genes and with an under-
standing of the unique qualities of their biology. Al-
though the GENCODE annotation comprises the largest
public dataset with 15,877 lncRNA genes (version 21:
http://www.gencodegenes.org/stats/archive.html#a21),
later studies that used several thousand normal and ma-
lignant samples from numerous individuals identified
four-fold more lncRNA genes [29]. Why the number of
lncRNAs continues to rise apparently in excess of
protein-coding gene number, is not yet clear. In this
study we set out to annotate the lncRNA transcriptome
of freshly harvested human granulocytes with the goal of
investigating lncRNA inter-individual expression vari-
ability and determining how this influences lncRNA
identification.
The resulting human granulocyte transcriptome obtained
from 10 healthy individuals identified 1,591 lncRNA loci
with a mean of 3.9 transcripts per locus. The same granu-
locytes express approximately six-fold more mRNA loci
each with approximately three-fold more transcripts. The
reduced activity of lncRNA loci relative to protein-coding
loci has been noted [14, 62]. Comparing the granulocyte
de novo annotation to the most commonly used public an-
notations (GENCODEv19: 23,898 lncRNA transcripts
[58], RefSeq: 8,236 lncRNA transcripts [59], Cabili: 21,630
lncRNA transcripts [14]) that together contain 19,762
non-overlapping lncRNA loci, shows that one-third of
granulocyte de novo lncRNA transcripts are not present
and one-third added a new isoform to public-annotated
loci. A comparison with the recent massive MiTranscrip-
tome lncRNA annotation containing 46,331 new lncRNA
loci [29], showed that 268 granulocyte lncRNA loci (17 %
of the annotated granulocyte lncRNA transcriptome) were
not previously reported. With the caveat that different an-
notation pipelines may influence identification, this shows
that human granulocytes have a specific lncRNA landscape
that needs to be defined prior to transcriptome analysis,
rather than relying on integrative lncRNA landscapes from
multiple cell types.
The identification of numerous new human granulo-
cyte lncRNA loci is surprising in view of the extremely
large numbers present in public annotations or datasets.
Because of this we investigated if specific lncRNA biol-
ogy features contribute to their under-representation in
public databases by assessing if they were more promin-
ent in new loci or isoforms. We first investigated four
known features, that is, very tight tissue-specific expres-
sion, lower expression level, inefficient enrichment in
PolyA+ selected fractions, and inefficient splicing
(reviewed in [30, 34, 40]). In each case we demonstrated
a significant difference for these features between
lncRNAs and mRNAs and, in addition, demonstrated
that these features are more prominent in new lncRNA
loci and transcript isoforms. For example, reports from
different species show that lncRNAs compared to
mRNAs have tight tissue-specific expression and also
are generally more lowly expressed [14, 15, 17, 18, 25,
65]. We found that while only 4 % of mRNA transcripts
display granulocyte-specific expression, 32 % of lncRNA
transcripts, and 57 % of novel lncRNA transcripts were
granulocyte-specific. Similarly, lncRNA expression levels
were 10-fold less abundant than mRNAs, as reported in
many species (see above references), however expression
of novel ‘not in PA’ lncRNA transcripts was 13-fold less
abundant. We could also show that lncRNA enrichment
in the PolyA+ fraction relative to total ribosomal-
depleted fraction was reduced compared to mRNAs (re-
spective median enrichments of 1.6-fold and 2.6-fold) in
agreement with findings that a proportion of lncRNAs
are not polyadenylated [66] and that this reduction was
1.6-fold greater for novel ‘not in PA’ lncRNA transcripts.
A relatively new feature reported for imprinted cis-re-
pressor lncRNAs such as Airn and Ube3a-ats [67, 68]
and for some lncRNAs in human K562 cells [45] that
could also affect the abundance of full-length transcripts
in PolyA+ RNA fractions, is inefficient splicing. We
accessed splicing efficiency of lncRNAs and mRNAs in
our granulocyte data and showed that compared to
mRNAs, lncRNAs are less efficiently spliced with a
broad distribution of splicing efficiency. Median lncRNA
splicing efficiency was reduced by 10.9 % compared to
mRNAs, however, novel lncRNA transcripts showed
22.9 % reduction. We confirmed the inefficient splicing
of lncRNAs and the greater reduction in novel lncRNA
using the independent MiTranscriptome annotation
[29]. Together this analysis shows not only that lncRNAs
share several non-mRNA-like biology features, but also
that these features are more prominent in new lncRNA
loci and transcript isoforms and thus are likely to reduce
lncRNA representation in public annotations.
The last feature examined that could influence the in-
complete representation of lncRNAs in public databases
is that of natural expression variation. We used the gran-
ulocyte annotation with seven donors sampled at three
time points separated by at least 1 month, to estimate
the natural expression variability of lncRNAs relative to
mRNAs. This analysis shows that lncRNA expression is
unexpectedly highly variable among a population and,
while relatively stable over time within an individual,
lncRNA expression variation is significantly larger than
that of mRNAs independent of expression level. We find
that when considering all the 6,249 de novo annotated
granulocyte lncRNA transcripts only 40 % (2,490) are ro-
bustly expressed, while 17 % (1,069) display significant
inter-individual variable expression even within the small
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sample size of seven donors. Importantly, we show that
high natural expression variability is not a consequence
of the generally low expression of lncRNAs, as lncRNA
transcripts/loci in all expression bins were more variable
than mRNAs and also displayed higher percentage of
significant inter-individual variable expression assessed
by ANOVA test. The high inter-individual variability of
lncRNA expression was unique enough to allow un-
supervised grouping of replicates sampled over several
months according to each of the seven donors. We veri-
fied high lncRNA inter-individual expression variability
by demonstrating a similar difference for MiTranscrip-
tome annotated transcripts expressed in granulocytes.
We also analyzed an independent public RNA-seq lym-
phoblastoid cell dataset from GEUVADIS [50]. This LCL
dataset derived from 462 donors displayed an overall
higher median expression variability for both mRNAs
and lncRNAs than the granulocyte dataset consisting of
seven donors; however, the relative two-fold difference
between lncRNAs and mRNAs loci and transcripts was
similar. In each of the three above analyses we could
show that novel lncRNA transcripts display higher ex-
pression variability than known lncRNA transcripts.
Lastly, we demonstrated that high lncRNA inter-
individual expression variability relative to mRNAs is a
general phenomenon in human tissues, by analyzing
multiple tissues from the GTEx project [64]. Interest-
ingly, although we analyzed the same number of donors
per tissue we found different absolute levels of lncRNA
and mRNA expression variability, with skeletal muscle
displaying the highest and LCL, nerve, and thyroid
displaying the lowest variability level. As an important
control, analyzing LCL in the GTEx dataset using the
MiTranscriptome annotation showed similar levels of
expression variability as that obtained by analyzing the
GEUVADIS LCL dataset using our de novo LCL annota-
tion. Overall, these expression variability analyses of
public datasets, in additional to our granulocyte analysis
presented here, confirm our conclusions and support the
general nature of increased lncRNA natural expression
variability compared to mRNAs.
Comparison of lncRNA and mRNA expression vari-
ability was performed as a small part of two previous
studies. One LCL study analyzing splicing variability of
protein-coding genes found a small number (183) of
GENCODE lncRNAs with consistent higher expression
variability than mRNAs, even in the absence of repli-
cates [69]. The second study [55] reported a similar rela-
tive impact of inter-tissue and inter-individual variability
to total variance in gene expression for highly expressed
(median RPKM >2.5 among 1,641 analyzed samples com-
prising 43 body sites from 175 individuals) GENCODE-
v12 lncRNAs and mRNAs. This implies, given the known
increased inter-tissue variability of lncRNAs, that
inter-individual variability of lncRNAs is also greater
in its absolute value than that of mRNAs. This study
additionally reported enrichment of lncRNAs among
genes showing differential expression between individ-
uals of different populations. Thus, the findings from
both these studies are consistent with our demonstra-
tion here of higher natural expression variation of
lncRNAs compared to mRNAs.
High lncRNA inter-individual expression variability
highlights another striking biology feature that distin-
guishes lncRNAs from mRNAs. The finding that expres-
sion variability is more prominent in new lncRNA loci
and reduced in reference lncRNA annotations also indi-
cates it can influence identification. Thus public annota-
tions based on limited numbers of human donors or
derived from single animal or plant inbred strains, may
have reduced representation of variably expressed
lncRNAs. We demonstrate this with the GEUVADIS
LCL RNA-seq data derived from one cell type, by show-
ing that adding more donors to the analysis identifies
more lncRNA genes in the human genome. The number
of lncRNA loci increased continuously, with novel
lncRNA showing a more striking increase than known
lncRNAs. The MiTranscriptome study that used a donor
number per tissue comparable to our LCL analysis [29]
identified three-fold more novel lncRNAs than present
in the three commonly used public databases (see above
references). Our results also indicate that a granulocyte
lncRNA annotation based on 10 donors, is most likely at
the lower part of the donor saturation curve for this cell
type. Moreover, our finding that the identification of
novel lncRNA loci does not plateau even with 120
donors indicates that comprehensive annotation of
lncRNAs in the human genome requires as many indi-
viduals as possible. The identification of high lncRNA
intra- and inter-individual expression variability has im-
plications for identifying lncRNAs and assessing their
function and potential medical use. LncRNAs that lack
consistent expression in some individuals are unlikely to
be necessary for normal cell function, but may be func-
tional in an age, environment, lifestyle, or disease related
manner as shown for some protein-coding genes [54, 70].
At the same time, it cannot be assumed that a robustly
expressed lncRNA has an important function in the cell
type in which it is expressed. For example, the develop-
mentally important Airn lncRNA retains robust expres-
sion after performing its silencing function [71]. Our
results support the view that functional studies require an
understanding of basic lncRNA biology in different indi-
viduals before they can be interpreted [36, 72].
The basis of increased inter-individual expression
variation of lncRNAs relative to mRNAs is unknown. It
may be relevant that, together with a lower conservation
and faster evolution rate, human lncRNAs are recently
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evolved loci, harboring more SNPs than protein-coding
genes [49, 73]. LncRNAs may also be more susceptible
to environmental and lifestyle factors that contribute to
mRNA expression variation [54]. Studies of protein-
coding genes and lncRNAs in LCLs prepared from dif-
ferent population groups conclude that both expression
strength and alternative splicing contribute to expression
variability [50, 69, 74, 75]. How this contributes to differ-
ences in lncRNA and mRNA expression variability is not
known. Bidirectional lncRNAs that likely share a pro-
moter with a neighboring protein-coding gene are regu-
lated similarly to neighboring protein-coding genes [76]
and we show that compared to intergenic or antisense
lncRNAs, expression variability of bidirectional lncRNAs
is more similar but still greater, than that of mRNAs.
Inter-individual alternative splicing may contribute as
some lncRNA loci display unusually high alternative
splicing and variable exon structures [77]. However, this
is not supported by our observation that expression vari-
ation over the whole locus is similar to that of transcript
isoforms. LncRNA genes are considered to be similar to
mRNA genes as both are transcribed by RNAPII (reviewed
in [30, 34]). However, details of their promoters or en-
hancers that could explain the five non-mRNA-like
features highlighted here (tight tissue-specificity, low
expression, inefficient PolyA+ selection, inefficient
splicing, and high inter-individual expression vari-
ation) have not yet been investigated. Some potential
gene regulatory features (chromatin-modification patterns,
splicing signals) are similar for lncRNAs and mRNAs
[14, 18, 25, 78]. Some publications identified non-
mRNA-like features in lncRNAs while others stress
mRNA-like features, particularly of intergenic lncRNAs
[15, 46, 79–81] (reviewed in [30, 34, 40]). The analysis
of healthy granulocytes presented here supports the view
that a lncRNA subpopulation shows distinct non-mRNA-
like features, which now includes high inter- and intra-
individual expression variability. Non-mRNA-like features
of lncRNAs may have use in their classification, as it is
likely to be relevant for their function [82, 83]. We show
here that in healthy granulocytes only 40 % (2,490) of
lncRNA transcripts are robustly expressed, while 17 %
(1,069) of lncRNA transcripts show significant variable ex-
pression. The biological significance of robust or variable
expression is not yet clear and both classes of lncRNAs
may be useful for some studies. However, explanations of
lncRNAs in terms of their evolution and function or pro-
posals of their use as biomarkers or therapeutic targets
first require an understanding of the robustness of their
expression in healthy tissues.
Conclusions
We demonstrate here by analysis of human granulocyte
RNA-seq data from multiple individuals that lncRNAs
show unusually high natural expression variability com-
pared to mRNAs. We use this dataset to generate a list
of robustly and variably expressed granulocyte lncRNAs
that will be of use in future applications. We also show
that higher expression variability of lncRNAs is a general
phenomenon inherent to diverse human tissues and cell
lines that is of yet, unknown biological significance. High
natural expression variability of lncRNAs, in addition to
their tight tissue-specificity, low expression, inefficient
PolyA+ selection, and inefficient splicing, identifies a set
of five non-mRNA-like features that distinguish part of
the lncRNA population from mRNAs and, also reduces
their representation in reference annotations. We show
that high inter-individual expression variability offers
one explanation for the incomplete annotation of
lncRNAs in many genomes. Our analysis shows that in-
creasing the number of individuals analyzed will identify
more lncRNA loci in the human genome, however, the
donor number required is vastly in excess of that re-
quired for mRNAs. The finding of high expression vari-
ability of lncRNAs and its effect on identification
provides novel guidelines for lncRNA annotation and
additional considerations for design of functional studies
and personalized medicine approaches.
Methods
Sample collection from healthy donors
Ten volunteers (five men, five women; age range: 27–62
years) without obvious disease were recruited to donate
blood. Seven volunteers donated blood three times with
gaps of 5 to 21 weeks (Additional file 2A). The remain-
der donated once only. Donors abstained from eating on
the morning of donation; 45 mL of venous blood was
collected between 10:00 and 11:00 into VACUETTE®
Sodium Citrate Coagulation Tubes and processed imme-
diately. Granulocytes were isolated using density gradient
centrifugation and immediately used for RNA preparation
either depleted for ribosomal RNA using the RiboZero
rRNA removal kit Human/Mouse/Rat (Epicentre) or a
polyA enriched using the TruSeq RNA Sample Prep Kit
v2 (Illumina) (details in Additional file 1: Supplemental
Methods).
RNA-seq library preparation and read alignment
(a) Non-strand-specific libraries were prepared using the
TruSeq RNA Sample Prep Kit v2 (Illumina) following
the manufacturer’s protocol. (b) Strand-specific library
preparation used same kit with modifications [84]. Equal
concentrations of barcoded libraries were pooled for
50 bp or 100 bp paired-end sequencing by Illumina
HiSeq 2000 (Biomedical Sequencing Facility http://bio
medical-sequencing.at/). After base-calling and sample
de-multiplexing, the RNA-seq data were provided as ar-
chived .fastq or unmapped .bam files. RNA sequencing
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reads were aligned using STAR aligner with adjusted
default parameters [56] (details in Additional file 1:
Supplemental Methods).
RNA-seq read number
Three stranded samples were sequenced per flow cell
lane generating 22 to 79 million 100 bp PE reads per
sample. Unstranded PolyA+ RNA-seq samples varied
from 24 to 38 million 100 bp PE and 64 to 91 million
50 bp PE reads. In total we obtained 17 PolyA+ RNA-
seq datasets and 21 total RNA-seq dataset totaling 2.13
billion reads (Additional file 2B).
Annotating mRNAs and lncRNAs in primary granulocytes
A total of 784 million PolyA+ RNA-seq reads from 10
donors were used to de novo annotate lncRNA and
mRNA transcriptomes in granulocytes (see details in
Additional file 1: Supplemental Methods). The final de
novo annotation of human primary granulocytes was
132,864 mRNAs forming 10,092 genomic loci (average
13.2 transcripts per locus) and 6,249 lncRNAs forming
1,591 genomic loci (average 3.9 transcripts per locus).
Assembly quality was assessed by inspecting de novo an-
notation of well-known lncRNAs like XIST (Additional
file 1: Figure S2A) and by analyzing completeness of as-
sembly of RefSeq (Additional file 1: Figure S2B) and
GENCODE-v19 (Additional file 1: Figure S2C) anno-
tated mRNAs.
Positional classification of lncRNAs
lncRNA loci and transcripts were divided into three clas-
ses based on their relative position to protein-coding
genes. We combined de novo mRNA annotation with
public protein-coding gene annotations by GENCODE-
v19 and RefSeq to obtain the most comprehensive anno-
tation of protein-coding genes in granulocytes. We then
called lncRNA loci/transcripts bidirectional if they
shared or overlapped a promoter (defined as TSS +/-
1.5 kb) with a protein-coding gene. LncRNA loci/tran-
scripts overlapping a protein-coding gene in the anti-
sense direction were called ‘antisense’ (sense direction
overlaps were removed from the annotation). The third
position-based class ‘intergenic’, had no overlap with a
protein-coding gene.
Cloning of full-length lncRNA transcripts
RT-PCR was performed on granulocyte cDNA to amp-
lify full-length lncRNA transcripts prior to cloning. PCR
primers (http://biotools.umassmed.edu/bioapps/primer3_
www.cgi) spanned the transcript from first to the last exon
and the PCR product length limited to 1.5 kb (Additional
file 2F). Isolated plasmid DNA was Sanger Sequenced and
aligned to the human genome using BLAT. Cloned se-
quences are displayed as a UCSC screen shot with the
de novo lncRNA annotation, primers, and BLAT align-
ment (Additional file 1: Figures S4-S8). Seventy-five
cloned sequences were submitted to GENBANK
(Additional file 2G).
Public RNA-seq data mining
We downloaded publicly available raw strand-specific
RNA-seq data (fastq files) from various cell types/tissues
produced by the ENCODE project and Illumina Human
Body Map Project (see list in Additional file 2H),
processed it as for other sequencing data in the study
(see: RNA-seq read alignment).
RPKM
This was calculated using RPKM_count.py (RSEQC
package). Expression of a transcript is the RPKM of
exons of a one transcript, expression over a locus is
RPKM of the whole locus including intronic signal.
Splicing efficiency analysis
We estimated splicing efficiency for each splice site of
each multiexonic transcript in our ribosomal-depleted
granulocyte RNA-seq from seven donors with three time
points pooled at the alignment stage to increase cover-
age. Splicing efficiency of each splice site was calculated
separately in each donor. We calculated RPKM of the
exonic and intronic boundaries of the splice site (45 bp
each, leaving out 5 bp directly at the splice site to allow
for imprecision of splice site identification), calculated
the ratio of intronic to exonic signal, and by that estimated
how efficiently this splice site was used (Additional file 1:
Figure S13A). A splice site was discarded if exonic RPKM
was below the cutoff (RPKM= 0.2) in any of the seven do-
nors. We then introduced a value ‘Splicing efficiency’ (S),
ranging from 0 for completely unused splice sites (intronic
signal equal or higher than exonic signal) to 100 for
optimally used spliced splice sites (no intronic signal de-
tected). S = 100*(1-RPKMintronic/RPKMexonic). We re-
placed all the negative S values (when intronic signal was
higher than exonic signal) with 0, defining such cases as
full absence of splicing. We averaged the splicing effi-
ciency value calculated from seven donors for each
splice site. Splicing efficiency of a transcript was then
defined as the maximal splicing efficiency achieved by
the most efficiently spliced site of that transcript.
Splicing efficiency of a locus was similarly defined by
the maximal splicing efficiency among all transcripts
(all splice sites) in the locus.
Assigning P value to boxplot comparisons
Every boxplot was plotted using values for all the tran-
scripts/loci analyzed (number of transcripts/loci indi-
cated in the boxplot). The difference in population sizes
of compared transcript/loci types was accounted for by
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performing statistical tests on equalized population sizes.
Namely, the larger population was randomly subsampled
to match the size of smaller population and Mann–
Whitney U test was applied to estimate significance of
the difference between the populations with equalized
sizes. Subsampling and statistical tests were performed
three times for each comparison and the three P values
obtained were averaged to give the resulting P value to
be indicated on the boxplot.
Inter-individual expression variability analysis
Inter-individual expression variability was estimated by
calculating standard deviation of expression between an-
alyzed donors then normalizing it to the mean expres-
sion of the locus/transcript among all analyzed donors.
For granulocytes we assessed variability between seven
donors (expression of a locus/transcript in each donor
was calculated as a mean of expression of the three time
points of this donor). For LCL we assessed variability be-
tween 462 donors.
GEUVADIS project RNA-seq data analysis
We downloaded and aligned using a common pipeline
all 462 PolyA+ 75 bp paired end RNA-seq raw sequen-
cing datasets provided by GEUVADIS RNA-seq project
(http://www.ebi.ac.uk/ena/data/view/ERR188021-ERR1884
82). The data contained donors from five populations
(http://www.1000genomes.org/category/frequently-asked-
questions/population). We picked two female and two
male unrelated donors from each population and used
RNA-seq from these 20 donors to assemble the LCL de
novo lncRNA and mRNA transcriptome. We pooled the
samples into five groups with a similar number of aligned
spliced reads (Additional file 2I) and performed transcrip-
tome assembly following the pipeline described for granu-
locytes. As the RNA-seq datasets were not strand-specific
we used strand-specific PolyA+ RNA-seq of GM12878
from the ENCODE project (Additional file 2H) in the
pipeline where needed. Quality assembly (Additional file 1:
Figure S24B) was assessed as for granulocytes.
GTEx RNA-seq data analysis
Aligned (as described in [55]) RNA-seq data from the
GTEx project (http://www.gtexportal.org/home/) were
downloaded from dbGaP (https://dbgap.ncbi.nlm.nih.gov/
) as described in (http://www.gtexportal.org/static/misc/
GTEx_Poster_CommunityMeeting_TY.pdf) after we ap-
plied and were granted data access. We downloaded
RNA-seq data for nine tissues (namely lymphoblastoid cell
line (LCL), adipose, artery, cerebellum, heart, lung,
muscle, nerve, and thyroid), from 10 male and 10 female
individuals each (Additional file 2J). The aligned RNA-seq
datasets were unstranded and ranged from 14.8 to
85.4 (average 52.1) million paired-end reads each. We
calculated RPKM of MiTranscriptome annotated multi-
exonic lncRNAs and mRNAs in all samples and
performed variability analysis between 20 individuals
per tissue.
Donor saturation curve
One hundred and twenty out of 462 GEUVADIS RNA-
seq samples containing more than 25 million reads were
picked for the analysis from 12 unrelated women and men
from each of the five population groups. A total of 25 mil-
lion reads were randomly sampled from each RNA-seq
sample using DownsampleSam.jar (Picard tools http://
broadinstitute.github.io/picard/command-line-overview.
html#DownsampleSam). Donors were grouped into 30
groups each with two women plus two men from the
same population and the reads from the four donors were
pooled using MergeSamFiles.jar (Picard tools http://broad
institute.github.io/picard/command-line-overview.html#
MergeSamFiles) to produce 30 × 100 million read pools.
Cufflinks was used to assemble a transcriptome from each
pool (Additional file 1: Supplemental Methods) resulting
in 30 transcriptome assemblies. Of these 30 assemblies, 1,
2, 3, 4, 5, 6, 8, 10, 15, 20, 25, or 30 assemblies were used to
annotate de novo LCL transcriptomes from different num-
ber of donors (4, 8, 12, 16, 20, 24, 32, 40, 60, 80, 100, and
120, respectively) and to define the relation between the
number of loci (Y axis) and the number of donors/assem-
blies (X axis). We randomly picked the needed number of
assemblies from the list of 30. The random picking was
performed three times for each number of assemblies
(Additional file 1: Figure S31B), except when all 30 assem-
blies were used for the last point. The picked assemblies
were then merged with Cuffmerge and underwent the pre-
viously established de novo annotation pipeline (Additional
file 1: Supplemental Methods).
Ethics statement
Peripheral blood samples were collected from healthy
volunteers after written informed consent at the Vienna
General Hospital (Allgemeines Krankenhaus der Stadt
Wien, Klinische Abteilung für Hämatologie und Hämos-
taseologie). The study was approved by the local Ethics
committee of the Medical University of Vienna (‘Ethik
Kommission der Medizinischen Universität Wien’)
and experimental methods comply with the Helsinki
Declaration.
Availability of data
Raw granulocyte RNA-seq data, RPKM, and variabil-
ity values for granulocyte de novo lncRNAs and
mRNAs as well as their BED12 annotation files were
deposited in NCBI's Gene Expression Omnibus [85]
and are accessible through GEO Series accession
number GSE70390 (http://www.ncbi.nlm.nih.gov/geo/
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query/acc.cgi?acc=GSE70390). LncRNA annotations in
granulocytes and LCL created in the study are available to
directly download as Additional files in bed12 format.
Genbank accession numbers for sequenced lncRNAs
are listed in Additional file 2G.
Additional files
Additional file 1: Supplemental Figures (S1-S35) with legends and
Supplemental Methods. (PDF 8255 kb)
Additional file 2: A Human granulocyte samples sequenced in this
study. B List of human granulocyte RNA-seq datasets produced in the
study. C Pools used for human granulocyte transcriptome assembly. D
Well-known lncRNAs used to adjust RNAcode and CPC pipeline output.
E Validation of de novo granulocyte lncRNA splice junctions by means of
exon spanning RT-PCR. F Validation of de novo granulocyte lncRNA
transcripts not supported by public annotations by means of cloning and
Sanger Sequencing: overview. G Validation of de novo granulocyte lncRNA
transcripts not supported by public annotations by means of cloning and Sanger
Sequencing: sequencing results and Genbank accession numbers. H Overview
of the publicly available RNA-seq datasets used in the study. I Pools used for
human LCL transcriptome assembly (GEUVADIS raw RNA-seq data used - [50]).
J Overview of the GTEx RNA-seq datasets used in the study. (XLSX 127 kb)
Additional file 3: Granulocyte de novo lncRNA loci annotation
(1,561 loci): BED12 formatted file can be directly uploaded into
UCSC browser. Column 5 indicates number of transcripts in the locus.
(BED 119 kb)
Additional file 4: Granulocyte de novo lncRNA transcript annotation
(6,249 transcripts): BED12 formatted file can be directly uploaded
into UCSC browser. (BED 655 kb)
Additional file 5: Granulocyte de novo mRNA loci annotation
(10,092 loci): BED12 formatted file can be directly uploaded into
UCSC browser. Column 5 indicates number of transcripts in the locus.
(BED 765 kb)
Additional file 6: Granulocyte de novo mRNA transcript annotation
(132,864 transcripts): BED12 formatted file can be directly uploaded
into UCSC browser. (BED 23458 kb)
Additional file 7: A List of robust lncRNA transcripts in
granulocytes (2,825 transcripts): columns are formatted as a BED12
file. B List of robust well expressed (RPKM >1) lncRNA transcripts in
granulocytes (931 transcripts): columns are formatted as a BED12 file.
(XLSX 250 kb)
Additional file 8: Annotation of granulocyte de novo lncRNA
transcripts showing significantly variable expression (1,069
transcripts): BED12 formatted file can be directly uploaded into
UCSC browser. (BED 117 kb)
Additional file 9: LCL de novo lncRNA loci annotation (2,611 loci):
BED12 formatted file can be directly uploaded into UCSC browser.
Column 5 indicates number of transcripts in the locus. (BED 197 kb)
Additional file 10: LCL de novo lncRNA transcript annotation (8,560
transcripts): BED12 formatted file can be directly uploaded into
UCSC browser. (BED 884 kb)
Additional file 11: Donor saturation curve samples and pools:
overview with list of donors, assemblies, and number of loci
identified using different number of donors. A List of 120 donors
used in the donor saturation study with corresponding population and
pool it was grouped into. B List of randomly picked pools for each data
point. C Number of de novo lncRNA and mRNA loci annotated using
different number of transcriptome assemblies (donors) – data for plotting
Fig. 7b, S32C-E and S34. D Number of de novo lncRNA and mRNA
loci from ‘120 donors’ annotation identified using less transcriptome
assemblies (donors) - data for plotting donor saturation curve - Figure S35A.
E Number of de novo lncRNAs from different expression bins identified from
increasing number of donors - data for plotting Figure S33. (XLSX 34 kb)
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